Skip to main
CSTL
CSTL logo

CSTL Stock Forecast & Price Target

CSTL Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Castle Biosciences Inc. demonstrates a compelling growth trajectory, with its TissueCypher test volume experiencing a substantial 92% year-over-year increase and a 23% quarter-over-quarter increase in the second quarter of 2025. This surge in test volume is anticipated to be bolstered by ongoing expansions to the sales force, with expectations for the gastrointestinal sales team to reach maturity in the second half of 2025, which suggests enhanced sales and operational efficiency. Additionally, the company has improved the gross margin of its TissueCypher test over time, underscoring its ability to enhance profitability alongside revenue growth, particularly when compared to slower growth in its DecisionDx-Melanoma product.

Bears say

Castle Biosciences Inc. faces a negative outlook primarily due to anticipated lower EV-to-estimated revenue multiples for its dermatology and DecisionDx-UM tests compared to its TissueCypher product. The reliance on the DecisionDx-Melanoma for revenue generation poses a risk, as most of the company's income stems from this single product line, making it vulnerable to market fluctuations. Despite appearing significantly undervalued based on current levels and conservative estimates, these factors indicate potential challenges in achieving sustainable revenue growth and maintaining investor confidence.

CSTL has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Castle Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Castle Biosciences Inc (CSTL) Forecast

Analysts have given CSTL a Buy based on their latest research and market trends.

According to 6 analysts, CSTL has a Buy consensus rating as of Oct 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Castle Biosciences Inc (CSTL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.